We used “RASless” MEF lines expressing mutant HRAS to investigate whether some of the more common co-mutations observed in human tumors affected their response to growth inhibition by tipifarnib, which is currently in clinical development for HRAS-mutant cancers. This evidence concerns the gene HRAS and cancer.